phase readout

NCT06149481: Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

RECRUITINGupdated 1mo ago

community read0 votes

Sponsor: National Cancer Institute (NCI). Phase: PHASE1. Conditions: Metastatic Colorectal Cancer

Data sources

last refreshed 1h ago

Found something off?

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?